In vitro restimulation experiments and in vivo depletion studies have shown that both CD4+ and CD8+ cells contribute to antitumor activity. Using PBMC from healthy volunteers and patients with HCC, it was shown that ASPH stimulation led to significant development of antigen-specific CD4+ T cells. Here, CD4 is linked to hepatocellular carcinoma.